Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genomic pathways to antifungal discovery.

Brian C Monk1, Richard D Cannon

  • 1Molecular Microbiology Laboratory, School of Dentistry, University of Otago, PO Box 647, Dunedin, New Zealand. brian.monk@stonebow.otago.ac.nz

Current Drug Targets. Infectious Disorders
|February 7, 2003
PubMed
Summary

Limited antifungal drugs face resistance and toxicity. Genome sequencing and functional genomics offer new strategies for discovering effective antifungal therapies against serious fungal infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of in vitro and in vivo antifungal activities of a deuterated tetrazole-based CYP51 inhibitor.

Bioorganic chemistry·2026
Same author

Nanocellulose Alleviates Intrahepatic Cholestasis of Pregnancy via Gut Microbiota-Mediated Bile Acid Homeostasis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Reduced FBXO22 skews human trophoblast fate equilibrium toward syncytialization via polyubiquitinating the CoREST complex.

Nucleic acids research·2026
Same author

The dual role of azoles: lifesaving antifungals and drivers of resistance - a One Health perspective.

Nature communications·2026
Same author

Dysregulation of Oral Microbial Eicosapentaenoic Acid Induced by Chronic Restraint Stress Exacerbates Periodontitis via M1 Macrophage Polarization.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

G521 is the gatekeeper and a key transmembrane domain contact residue of <i>Candida albicans</i> Cdr1.

mBio·2026

Area of Science:

  • Medical Mycology
  • Genomics
  • Drug Discovery

Background:

  • Current antifungal therapies exhibit limitations, including modest efficacy against systemic fungal infections, toxicity, and the emergence of drug-resistant fungal strains.
  • The limited number of available antifungal drug classes and targets, coupled with increasing antifungal resistance, necessitates the development of novel therapeutic strategies.

Purpose of the Study:

  • To review the application of functional and comparative genomic techniques in identifying new antifungal drug targets.
  • To highlight the contribution of genomic approaches to the discovery and optimization of antifungal leads.

Main Methods:

  • Genome-wide analysis of gene function in fungal pathogens.
  • Comparative genomics utilizing reference genomes like Saccharomyces cerevisiae and human.
  • Application of functional genomic techniques for target identification and prioritization.

Main Results:

  • Genomic information is rapidly expanding for significant fungal pathogens.
  • Functional and comparative genomics enable a comprehensive understanding of fungal biology.
  • These techniques facilitate the identification and prioritization of novel drug targets for antifungal development.

Conclusions:

  • Genomic approaches are crucial for addressing the challenges posed by antifungal resistance and limited therapeutic options.
  • The integration of functional and comparative genomics accelerates the discovery of effective antifungal agents.
  • Continued application of these techniques is vital for combating life-threatening fungal diseases.

Related Experiment Videos